PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries' board, at its meeting on April 8, 2025, approved the final call on 25 crore (25,00,00,000) convertible equity warrants allotted on a preferential basis to non-promoter investors. The company has received the remaining 15% call money of Rs. 0.27 per warrant, totalling about Rs. 6.30 crore, from three allottees: Parichay Infrastructure Ltd (8.2 crore warrants, Rs. 2.07 crore), Rama Shiva Lease Finance Pvt Ltd (8.4 crore warrants, Rs. 2.12 crore), and Interface Financial Services Ltd (8.4 crore warrants, Rs. 2.12 crore). With this final call, the warrants are now eligible to be converted into equity shares, which will lead to a significant expansion of the company's share capital base.
Once the warrants are converted into equity shares, the equity capital of the company will expand substantially, leading to dilution for existing shareholders. Short-term share price may face pressure due to the large pending dilution, though the company has secured the remaining funding from these allottees.